About this trial
Mitral valve leakage, or mitral regurgitation (MR), is associated with heart failure symptoms including shortness of breath, fatigue, irregular heart rate. When left untreated, it may cause death. Patients with MR can be divided in two broad groups: those with primary MR, caused by disease of the mitral valve structures, and those with secondary MR, due to dilation of the heart chambers. Our study focuses on patients with primary MR.
The standard treatment for severe symptomatic primary MR is mitral valve surgery, a type of open-heart surgery. The outcomes following this procedure are excellent, however, a subset of patients continue to experience heart failure symptoms after surgery due to very high pressures in the heart, more specifically in the left atrium, which is one of the four heart chambers. This is called functional mitral stenosis (FMS).
Previous studies have shown that creating a small opening between the left and right atria can help relieve the pressure inside the left atrium. We would like to determine whether creating this opening between the two atria at the time of mitral valve surgery can help prevent FMS. To answer this question, we will study two groups of patients who need mitral valve surgery for primary MR. The first group will undergo mitral valve surgery, along with the creation of the opening between the two atria. The second group will undergo mitral valve surgery alone. We will then compare the outcomes between both groups, namely with regards to their heart failure symptoms after open-heart surgery.
Eligibility criteria
Qualifiers
Patients ≥18 years of age
Severe (4+) symptomatic Carpentier Type II MR due to degenerative disease
Planned surgical mitral valve repair
Right-to-left atrial pressure gradient ≥ 5 mmHg at baseline
Disqualifiers
Secondary causes of MR and mixed mitral valve disease
Infective endocarditis within 30-days
Any prior mitral valve intervention
Need for emergency intervention or surgery
Trial design
Treatments tested in this trial
- Mitral valve repair with creation of an 8 mm inter-atrial shunt